中国第一个新冠疫苗进入临床试验，比预期提前近1个月。
China's first new vaccine entered clinical trials, nearly a month ahead of schedule.
健闻吴晔婷。
Nicknamed Wu selected.
八点健闻Plus                      。
Eight minutes plus.
八点健闻Plus。
Eight minutes plus.
八点健闻分号，好看的健康商业报道。
Eight Jianwen semicolon, Good-looking Health Business Report.
。
.
康希诺、军科院的重组病毒载体疫苗和Moderna的核酸疫苗，原理不同，但都是最新的技术。
Consino's recombinant viral vaccine and Moderna's nucleic acid vaccine are different in principle, but they are all state-of-the-art.
中国进度最快的新冠病毒疫苗，已经进入临床试验志愿者招募阶段。
China's fastest-growing vaccine for the new crown virus has entered the volunteer phase of clinical trials.
今天（3月17日）上午，康希诺生物－Ｂ(06185.HK)发布公告称，公司与军科院生物工程研究所联合开发重组新型冠状病毒疫苗(腺病毒载体)，目前已递交新药临床试验预审评申请，并启动健康志愿者预招募。
Today, March 17 morning, Consino Biology-B (06185.HK) announced that it had developed a recombinant new coronavirus vaccine (adenovirus vector) with the Institute of Biological Engineering of the Military Academy of Sciences.
官方消息验证了康希诺的进展。
Official sources confirmed Consino's progress.
今天下午，国务院联防联控机制发布会上，未点名地介绍了中国疫苗研发的最新进展——“第一批确定的9项疫苗研发任务，目前都已完成大部分临床前研究工作，包括动物有效性和安全性试验，预计大部分研发团队在4月份都能完成临床前的准备工作，并陆续启动临床申请、临床试验”。
This afternoon, at the launch of the Joint Prevention and Control Mechanism of the State Council, an unnamed update on the progress of vaccine development in China - "Most of the nine vaccine research and development tasks identified in the first batch have completed most of the pre-clinical research work, including animal efficacy and safety trials.
发布会上同时披露：“我国已经有研发进展比较快的单位向国家药监局滚动提交临床试验申请材料，并且开展临床试验方案的论证、招募志愿者等相关工作，待国家药监局按有关法律法规审批以后开展临床试验。
At the same time, the press conference revealed that: "China has a relatively fast development of research and development units to the State Drug Administration to roll over the application materials for clinical trials, and clinical trials, such as certification, recruitment of volunteers and other related work, pending approval by the State Administration of Pharmaceutical Supervision in accordance with relevant laws and regulations.
我国疫苗研发进展属于国际先进行列，不会慢于国外”。
China's vaccine development belongs to the international advanced ranks, will not be slower than foreign countries. "
这个进度比之前预计进入临床阶段的时间提前了近一个月。
This is nearly a month ahead of schedule for the clinical phase.
在3月6日国新办在湖北武汉举行新闻发布会上，中央指导组成员、国务院副秘书长丁向阳给到了一个最早的数据——多数疫苗研发预计4月中旬甚至更早申报临床试验。
At a press conference in Wuhan, Hubei Province, on March 6, Ding Xiangyang, a member of the Central Steering Committee and Deputy Secretary-General of the State Council, gave the first data - most vaccine research and development is expected to report clinical trials by mid-April or earlier.
从全球来看，进展最快的是美国Moderna公司，3月5日该公司疫苗“mRNA-1273”临床试验获批，昨天（3月16日），4名受试者在西雅图接受了疫苗注射。
Globally, the fastest-growing company is the US company Modern, which on March 5 approved clinical trials for its vaccine, mRNA-1273, and yesterday, March 16, four people were vaccinated in Seattle.
△来源：yestone康希诺和Moderna疫苗原理不同，但都是最新的技术康希诺的联合开发方正是此前因一张配文为“疫苗第一针，院士先试”的图片而备受关注的陈薇院士团队，尽管后来的报道证实这张照片中注射的并非新冠疫苗，但当时确实已有进展。
www.youtheme.cn www.youtheme.cn www.youtheme.cn www.youtheme.cn www.youtheme.cn www.youtheme.cn www.youtheme.cn www.youtheme.cn www.youtheme.cn The co-developers of the latest technology, Consino, were following closely watched Academician team with a picture of the vaccine being tested first.
当晚《新闻联播》指出“由军事医学研究院陈薇院士领衔的科研团队在新冠肺炎疫苗研制方面取得了重要阶段性成果”，不过并未指明具体的成果。
"The team, led by Academician Chen Weiwei of the Institute of Military Medicine, achieved important milestones in the development of the vaccine," the evening said, though no concrete results were specified.
直到今天，康希诺公告发布，该公司和军科院联合开发的疫苗Ad5-nCoV采用基因工程方法构建，以复制缺陷型人5型腺病毒为载体，可表达新型冠状病毒S抗原，用于预防新型冠状病毒感染引起的疾病。
The vaccine Ad5-nCoV, jointly developed by the company and the Academy of Military Sciences, was constructed using genetic engineering methods to express a new coronavirus S antigen to prevent new coronavirus infections by replicating the defective human-5 adenovirus as a vector.
这不是军科院第一次与康希诺合作。
This is not the first time the academy has worked with Conshino.
此前双方合作用同样的技术成功研发了埃博拉疫苗，并于2017年在国内完成审批上市流程。
Previously, the two sides worked together to develop a successful Ebola vaccine using the same technology, completing the approval process domestically in 2017.
一位熟悉陈薇团队的传染病学家告诉八点健闻，此次研发新冠疫苗，继续沿用了埃博拉疫苗式的复制缺陷型人5型腺病毒作为载体。
An infectious disease scientist familiar with Chen's team told Eight Keen Hei that the new vaccine continues to use the Ebola vaccine-like replication-defective human-5 adenovirus as a vector.
“腺病毒载体就像是酒瓶，我们现在把里面的白酒（埃博拉病毒）换成红酒（SARS-CoV-2病毒）了，而外面的酒瓶起到的保护作用是一样的。
"The adenovirus carrier is like a bottle of wine, and we now replace it with red wine (the SARS-CoV-2 virus), with bottles outside serving the same protective effect.
”具体来讲，重组病毒载体疫苗是指一种活载体疫苗技术，也是最新一代的疫苗技术。
Specifically, the recombinant viral vaccine is a live-carrier vaccine technology and the latest generation of vaccine technology.
其作用机制是，以病毒作为载体，将保护性抗原基因重组到腺病毒基因组中，使用能表达保护性抗原基因的重组腺病毒制成的疫苗。
It works by using viruses as vectors to recombine protective antigen genes into the adenovirus genome, using recombinant adenoviruses that express protective antigen genes.
以埃博拉疫苗为例，在病毒载体（腺病毒）中加入表达可供埃博拉病毒进入细胞的埃博拉糖蛋白EBO-GP的基因，病毒在细胞内表达出了减毒的埃博拉病毒，能够刺激B细胞及T细胞以诱发免疫力。
Consider the Ebola vaccine, in which a gene expressing the Ebola glycoprotein EBO-GP that allows the Ebola virus to enter cells is added to a viral vector (adenovirus), which expresses the attenuated Ebola virus in cells and stimulates B cells and T cells to induce immunity.
感染细胞时，因为不整合到染色体中，激活致癌基因或插入突变等风险低，生物安全性高。
Infection of cells, because they are not integrated into chromosomes, activation of carcinogenic genes or insertion of mutations, is low risk, and biosecurity is high.
根据这位传染病学家的估计，从现在开始算，到拿到上市许可证，哪怕在应急状态下，也至少还需要一年时间。
According to the infectious-diseases expert, it will take at least a year from now to get a listing license, even in an emergency.
从疫苗原理和工艺上区分，疫苗主要可以分为传统的灭活、减毒疫苗；亚单位疫苗/ 基因重组蛋白疫苗；病毒载体疫苗以及核酸疫苗(mRNA疫苗和DNA疫苗)。
In terms of vaccine principles and techniques, vaccines can be divided into traditional inactivated and attenuated vaccines; subunit / recombinant protein vaccines; viral vector vaccines; and nucleic acid vaccines (mRNA and DNA vaccines).
康希诺、军科院的重组病毒载体疫苗和Moderna的核酸疫苗，都是最新的技术。
Consino, the recombinant viral vector vaccine of the Academy of Military Sciences and the nucleic acid vaccine of Moderna are all the latest technologies.
核酸疫苗技术目前在全球范围内还没有成功上市的疫苗先例，与病毒载体疫苗技术用了病毒作为载体不同，mRNA技术将编码S蛋白的基因直接注入人体，利用人体细胞产生S蛋白，刺激人体产生抗体。
Unlike viral vector vaccine technology, which uses viruses as a vector, mRNA techniques inject genes encoding S proteins directly into the body, using human cells to produce S proteins that stimulate the body to produce antibodies.
目前来看，Moderna公司的疫苗是进展最快的。
At the moment, Moderna's vaccine is the fastest growing.
3月5日， Moderna宣布，美国食品药品监督管理局（FDA）已完成对该公司研制的新型冠状病毒mRNA疫苗——“mRNA-1273”的审查，批准其进入临床试验。
On March 5, Moderna announced that the United States Food and Drug Administration (FDA) had completed a review of its new coronavirus mRNA vaccine, mRNA-1273, and approved its entry into clinical trials.
据美联社报道，3月16日，4名受试者在华盛顿州西雅图市“凯撒医疗集团华盛顿健康研究中心”(Kaser Permannte Washinton Helth Reserch Institute)接受了疫苗注射。
On March 16, four people were vaccinated at the Kaser Permannte Washington Health Research Institute in Seattle, Washington, the Associated Press reported.
43岁的Jennfer Haller是第一个接种疫苗的志愿者，在mRNA-1273疫苗的临床1期试验中，共有45名志愿者，他们将在一个月内被注射两次剂量。
Jenny Haller, 43, the first volunteer to be vaccinated, will be injected twice a month in the first clinical trial of mRNA-1273.
疫苗试验如何展开？以埃博拉疫苗为例同药品研发过程一样，进入临床试验阶段之后，疫苗也需要经历三期临床试验，作为预防性疫苗，三期试验均以健康人群为受试对象。
In the case of the Ebola vaccine, as in the case of pharmaceutical research and development, three clinical trials of the vaccine are required after the clinical trial phase, with the three trials targeting healthy people as a preventive vaccine.
临床1期通常需要20-80位试验对象，以评估疫苗的安全性，确定疫苗引起的免疫反应类型和程度。
Clinical phase 1 usually requires 20-80 subjects to assess vaccine safety and determine the type and extent of immune response caused by the vaccine.
临床2期试验研究候选疫苗的安全性、免疫原性、建议的剂量、免疫接种计划和接种方法，由几百人组成的受试者小组参与。
The second phase of clinical trials involved teams of several hundred people to study the safety, immunogenicity, recommended doses, immunization schedules, and vaccination methods of candidate vaccines.
本阶段的目的是更详细地评估与1期相比的剂量和给药计划。
The aim at this stage is to assess in more detail the doses and delivery plans compared to phase 1.
在临床2期取得成功的基础上，候选疫苗将继续进入3期试验，试验人群从3千人至数万人不等。
Based on the success of clinical phase 2, the candidate vaccine will continue to undergo three trials, ranging from 3,000 to tens of thousands of people.
此阶段关键目标是评估疫苗的安全性和有效性。
The key objective at this stage is to assess the safety and efficacy of vaccines.
而在紧急情况下，会加快审批流程，简化试验对象数量。
In case of emergency, it will speed up the approval process and simplify the number of test subjects.
根据一家疫苗公司负责人的估计，新冠疫苗只要在临床3期阶段能看到30-50例有效，就可以进入上市流程了。
According to estimates by the head of a vaccine company, the new canopy vaccine will be ready to go on the market as long as 30-50 cases are seen to be effective in the third stage of clinical trials.
具体地，临床阶段试验如何展开，我们可以回顾一下该团队此前的埃博拉疫苗试验过程，以作参考。
Specifically, how the clinical trial unfolds, we can review the team's previous Ebola vaccine trial process for reference.
在康希诺的招股书中，详细记载了埃博拉疫苗的临床试验过程：第一阶段为国内临床试验（Ia期临床试验），针对的是中国受试人群。
In Conshino's prospectus, the clinical trial process for the Ebola vaccine was documented in detail: the first phase was a domestic clinical trial (phase Ia), aimed at Chinese subjects.
研发团队与江苏省疾控中心合作，在泰州完成了对120名年龄在18至60岁的健康成年人的随机双盲、剂量递增、安慰剂对照临床试验。
The research and development team, in collaboration with the Jiangsu CDC, completed a randomized double-blind, incremental, placebo-controlled trial in Taizhou province for 120 healthy adults aged 18 to 60.
60名受试者按照2:1的比例被随机分配接种低剂量或安慰剂对照。
Sixty subjects were randomly assigned low doses or placebo controls at a scale of 2: 1.
在最初低剂量和安慰剂对照组中显示安全性和耐受性七天之后，另外60名受试者按照2:1的比例被随机分配接种高剂量或安慰剂对照。
After showing safety and tolerance for seven days at first low doses and placebo controls, the other 60 subjects were randomly assigned high doses or placebo controls at a scale of 2: 1.
试验结果证实了疫苗的安全性和免疫原性，接种后14天达到预期免疫效果，28天抗体水平达到峰值。
The results showed that the vaccine was safe and immunogenic. The expected immune effect was achieved 14 days after inoculation, and the antibody level peaked at 28 days.
第二阶段依旧为国内临床试验（Ib期临床试验），针对的则是在华非洲人群。
The second phase, still a domestic clinical trial (Ib phase), is aimed at African populations in China.
研发团队与浙江大学第一附属医院合作，受试者为61位年龄在18-60岁的健康非洲人。
The research and development team teamed up with Zhejiang University's First Affiliated Hospital to test 61 healthy Africans aged 18 to 60.
研究同样表明了疫苗的安全性和免疫原性。
The study also showed the safety and immunogenicity of vaccines.
比较泰州临床和杭州临床的检测结果，并未发现非洲及亚洲种族群体之间在免疫反应上存在种族或人种差异。
A comparison of clinical results from Taizhou and Hangzhou did not reveal racial or ethnic differences in immune responses between African and Asian ethnic groups.
在得出这一结果后，研发团队带着疫苗到非洲去。
After arriving at this result, the research and development team took the vaccine to Africa.
于是临床试验进入了第三阶段（II期临床试验），也就是在非洲展开了境外试验，针对的是非洲人群，在塞拉利昂对500名年龄为18至50岁的健康成人进行的单中心、随机、双盲及安慰剂对照的试验。
Clinical trials thus entered the third phase (phase II clinical trials), which involved off-site trials in Africa, targeting the African population, and single-centre, randomized, double-blind and placebo-controlled trials in Sierra Leone of 500 healthy adults aged 18 to 50.
参与者按2:1:1的比例依次入组并随机分配接种高剂量疫苗、低剂量疫苗或安慰剂。
Participants were grouped in order of 2: 1 and randomly assigned high doses of vaccines, low doses of vaccines, or placebos.
试验结果表明，自接种后第14天起，高剂量组及低剂量组均至少有96%的受试者中检测到抗体应答，并于第28天达至高峰。
The results showed that antibody responses were detected in at least 96% of subjects in both high and low dose groups from day 14 and peaked at 28 days.
对健康的塞拉利昂成人而言，Ad5-EBOV具备安全性及令人满意的免疫原性。
Ad5-EBOV is safe and has satisfactory immunogenicity for healthy Sierra Leonean adults.
然而，抗体应答的持续时间较短，增加了初免-加强免疫接种的需要。
However, the short duration of the antibody response increased the need for primary and booster immunization.
至2017年，由于处于埃博拉流行间歇期，难以提供大样本量人群有效性数据，Ⅲ期临床试验无法开展。
By 2017, phase III clinical trials could not be carried out because of the difficulty in providing population validity data for a large sample because of the Ebola epidemic interlude.
针对这一状况，药审中心加快审评进程，根据当时已有研究得到的安全性和免疫原性数据，批准了重组埃博拉病毒病疫苗的有条件上市。
In response, the Centre accelerated the review process and approved the conditional release of the recombinant Ebola virus vaccine on the basis of safety and immunogenicity data from available research at that time.
上市后，重组埃博拉病毒病疫苗仅作为国家储备，用于疫情发生时的应急处理，并开展Ⅲ期临床试验。
Since its launch, the recombinant Ebola virus vaccine has been used only as a national reserve for emergency response in the event of an outbreak and to carry out phase III clinical trials.
△来源：GIPHY疫苗直接关系世界疫情的下一步走向至于疫苗最终能否顺利问世，“一方面与疫苗本身能否顺利研发成功相关，包括能否通过安全性的挑战；是否有很好的应答率和免疫原性，确实能在人体内产生免疫抗体；对疫苗目标人群是否有足够的保护效果；以及疫苗本身是否有持久性”，北京大学公共卫生学院卫生检验学系研究员、系主任崔富强分析称。
GIPHY vaccine is directly related to the next step of the world epidemic. The success of the vaccine depends on the success of the vaccine itself, including whether it can pass the safety challenge.
另一方面，也与疫情的发展相关。
On the other hand, it is also relevant to the development of the epidemic.
新冠病毒的发展有两种可能，一是像SARS一样，从此无踪无影，如果在临床试验阶段，疫情已经结束，病毒已经消失，那就无法继续开展临床试验，因为打了疫苗的实验组和没有打疫苗的对照组都没有机会感染病毒，就无法证明疫苗的有效性，试验也就无法科学开展。
There are two possible scenarios for the development of the new crown virus. If, like SARS, the outbreak is over and the virus has disappeared, clinical trials cannot continue because neither the vaccinated or the unvaccinated control have a chance to prove the effectiveness of the vaccine, and the trials cannot be conducted scientifically.
这种情况下做疫苗的可行性就不存在，理论上来说就不应该去做。
The feasibility of a vaccine in this case does not exist, and in theory should not be done.
二是可能这种病毒将来会重复出现，再次在人群中流行，那么做疫苗的必要性就非常大了。
Second, it is possible that the virus will reappear in the future and become popular again in the population, so the need for a vaccine is very great.
至于病毒会否在将来重复出现，还有待时间的检验。
It remains to be seen whether the virus will reappear in the future.
“比如说这次是在11月以后到现在流行，如果说我们把它时间段看成每年的11月到3月之间流行的这么一个大趋势的话，那么它应该在每年这个时候出现。
If we think of it as a big trend that goes around from November to March every year, it should show up at this time of year.
需要几年的数据才能说话，现在我们下结论，还为时过早。
It will take years of data to speak, and it is too early to draw conclusions.
”崔富强表示。
Mr Cui said.
而在今天国务院联防联控机制发布会上，教育部科技司司长雷朝滋说：疫苗作为疫情防控最有效的医学手段，可以有效的阻断病毒传播，不仅对中国取得抗击新冠疫情的最终胜利、稳定经济形势、有序复工复产具有重要的作用，而且直接关系世界疫情的下一步走向。
As the most effective medical means to prevent and control the disease, vaccines can effectively stop the spread of the virus, play an important role in China's ultimate success in fighting the new crown epidemic, stabilize the economic situation and resume production in an orderly fashion, and have a direct bearing on the future course of the epidemic, said Lei Chaozi, director of science and technology department of the Ministry of Education.
吴晔婷|撰稿微信号：wytlucky19王吉陆|责编微信号：wangjilu006致读者：“八点健闻”公众号将于4月11日恢复更新。
Wytlucky19 Wang, who compiles microsignals: wangjilu006 to readers: 'Eight Good News' will resume updating April 11.
在此之前，我们在“八点健闻Plus”发表报道。
Before that, we published a report at Eight Point Health Plus.
敬请关注。
Attention, please.
我们尊重原创版权，未经授权请勿转载。
We respect original copyright and do not reproduce without permission.
郑琪|授权转载微信号：1281949389商务合作上海：leslee 13916263824北京：Jessie 13911125922线索爆料、意见反馈，加入核心读者社群请扫码联系健闻君让朋友们看到你也在看↓↓↓。
CHENG Chi-chi & # 124; Authorize the Reproduction of Microsignals: 1281949389 Commercial Cooperation Shanghai: Leslee 13916263824 Beijing: Jessie 13911125922 Tracing tips, feedback, joining the core reader community, please sweep code to let friends see you, too.
健闻吴晔婷。
Nicknamed Wu selected.
信扫一扫赞赏作者。
The letter swept over the author.
已喜欢，对作者说句悄悄话。
Like it, whisper to the author.
发送给作者。
Send to author.
最多40字，当前共字。
Up to 40 words, currently in common.
发送到看一看 。
Send it to see.
中国第一个新冠疫苗进入临床试验，比预期提前近1个月。
China's first new vaccine entered clinical trials, nearly a month ahead of schedule.
查看更多相关内容。
See more for more information.
查看更多相关内容。
See more for more information.
以上推荐为优质及原创文章。
Above recommendations for quality and original articles.
长按识别前往小程序。
Long press identify to go to the applet.
var _ori_article_type = "健康医疗";。
var _ ori _ article _ type = & quot; Health & quot;;
var nickname = "八点健闻Plus";。
Var nickname = & quot; eight health plus & quot;;
var msg_title = "中国第一个新冠疫苗进入临床试验，比预期提前近1个月";。
var msg _ title = & quot; China's first new vaccine entered clinical trials, nearly a month earlier than expected;;
var msg_desc = "中美进度最快的疫苗原理不同，但都是最新技术";。
var msg _ desc = & quot; & # 160; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45;
var title ="八点健闻Plus";。
var title = & quot; eight health plus & quot;;
